CFB
AKRO

Cullen/Frost Bankers’s Akero Therapeutics AKRO Stock Holding History

Cullen/Frost Bankers’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-150
Closed -$3.5K – 996
2023
Q4 		$3.5K Hold
150
– – ﹤0.01% 899
2023
Q3 		$7.59K Buy
+150
New +$6.98K ﹤0.01% 952

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Cullen/Frost Bankers's AKRO Position: Q1 2024 in Review

Cullen/Frost Bankers sold out of Akero Therapeutics (AKRO) in Q1 2024, closing a stake of 150 shares — an estimated $3.5K sold.

Cullen/Frost Bankers first reported a position in AKRO in Q3 2023 and held it in 2 quarters. The position peaked at $7.59K in Q3 2023. 173 funds tracked by Wall St. Rank hold AKRO as of Q1 2024.

  • Cullen/Frost Bankers reported no remaining Akero Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cullen/Frost Bankers sold 150 Akero Therapeutics shares in Q1 2024, an estimated $3.5K.
  • Cullen/Frost Bankers first reported a position in Akero Therapeutics in Q3 2023 and held it in 2 quarters.
  • Cullen/Frost Bankers's Akero Therapeutics position peaked at $7.59K in Q3 2023.
  • 173 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2024.

Based on Cullen/Frost Bankers's 13F filing for Q1 2024, filed 10 May 2024.